Hapvida Participacoes e Investimentos (HAPV3) Q4 2023 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2023 earnings summary
1 Nov, 2026Executive summary
FY23 net revenue was R$27,383.4m, up 10.1% YoY; Adjusted EBITDA reached R$2,932.4m, up 47.6% excluding specified one-offs.
Margin recovery and robust cash generation reduced net debt leverage to 1.38x EBITDA, despite beneficiary declines.
Financial highlights
4Q23 net revenue was R$6,935.5m, up 6.7% YoY; Adjusted EBITDA was R$949.7m, with a 13.7% margin.
FY23 Adjusted Net Income was R$846.2m versus R$1,116.4m in 2022, excluding specified Premium and Promed adjustments; reported net loss was R$739.2m.
FY23 gross margin was 25.8%, up 2.6pp YoY; 4Q23 gross margin was 28.8%, up 5.6pp YoY.
FY23 CapEx was R$440.7m, down 40.1% YoY; 4Q23 CapEx was R$101m, down 86.6% YoY.
Segment performance
Health Plans revenue was R$26,560.4m in FY23, up 11.9% YoY; 4Q23 revenue grew 8.0% as average monthly ticket reached R$256.5.
Dental Plans revenue reached R$841.8m in FY23, up 6.5%; 4Q23 revenue rose 8.6% YoY to R$218.0m.
Hospital Services and Other Activities revenue declined 11.8% to R$1,318.6m in FY23; 4Q23 revenue fell 23.4% YoY, reflecting divestments and reduced third-party services.
Latest events from Hapvida Participacoes e Investimentos
- Revenue rose 3.9%, while litigation and higher claims cut adjusted EBITDA 33.5%.HAPV3
Q3 2026 - Revenue up 3.9% YoY, but EBITDA and net income down amid margin and litigation pressures.HAPV3
Q2 2026 - Net revenue rose 5.2% YoY to R$7.9B, with EBITDA at R$803M and improved cash MLR.HAPV3
Q1 2026 - Net revenue up 5.9% YoY, but margin and beneficiary base declined amid cost and competitive pressures.HAPV3
Q4 2025 - Net revenue up 6.0% YoY, adjusted EBITDA at R$746.4M, and cash MLR at 75.2%.HAPV3
Q3 2025 - Net revenue rose 7.3% to R$7.67B, with strong beneficiary growth and resilient margins.HAPV3
Q2 2025 - Revenue and margins improved, with net debt at 0.97x EBITDA and strong cash flow.HAPV3
Q3 2024 - Strong revenue and margin growth, improved cash flow, and reduced liabilities in 2024.HAPV3
Q4 2024 - Revenue up 7.3% YoY, leverage down to 0.98x, but adjusted net income declined on legal costs.HAPV3
Q1 2025